Literature DB >> 11301059

Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology.

D Smart1, J C Jerman, M J Gunthorpe, S J Brough, J Ranson, W Cairns, P D Hayes, A D Randall, J B Davis.   

Abstract

A full pharmacological characterisation of the recently cloned human vanilloid VR1 receptor was undertaken. In whole-cell patch clamp studies, capsaicin (10 microM) elicited a slowly activating/deactivating inward current in human embryonic kidney (HEK293) cells stably expressing human vanilloid VR1 receptor, which exhibited pronounced outward rectification (reversal potential -2.1+/-0.2 mV) and was abolished by capsazepine (10 microM). In FLIPR-based Ca(2+) imaging studies the rank order of potency was resiniferatoxin>olvanil>capsaicin>anandamide, and all were full agonists. Isovelleral and scutigeral were inactive (1 nM-30 microM). The potencies of capsaicin, olvanil and resiniferatoxin, but not anandamide, were enhanced 2- to 7-fold at pH 6.4. Capsazepine, isovelleral and ruthenium red inhibited the capsaicin (100 nM)-induced Ca(2+) response (pK(B)=6.58+/-0.02, 5.33+/-0.03 and 7.64+/-0.03, respectively). In conclusion, the recombinant human vanilloid VR1 receptor stably expressed in HEK293 cells acted as a ligand-gated, Ca(2+)-permeable channel with similar agonist and antagonist pharmacology to rat vanilloid VR1 receptor, although there were some subtle differences.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11301059     DOI: 10.1016/s0014-2999(01)00901-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

1.  Temperature oscillations drive cycles in the activity of MMP-2,9 secreted by a human trabecular meshwork cell line.

Authors:  Stanley Ka-Lok Li; Juni Banerjee; Christopher Jang; Amita Sehgal; Richard A Stone; Mortimer M Civan
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-05       Impact factor: 4.799

Review 2.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 3.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

4.  Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor.

Authors:  Kathy G Sutton; Elizabeth M Garrett; A Richard Rutter; Timothy P Bonnert; Wolfgang Jarolimek; Guy R Seabrook
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

5.  Mechanisms of acid-induced activation of airway afferent nerve fibres in guinea-pig.

Authors:  Marian Kollarik; Bradley J Undem
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

6.  Excitation of cutaneous C nociceptors by intraplantar administration of anandamide.

Authors:  Carl Potenzieri; Thaddeus S Brink; Donald A Simone
Journal:  Brain Res       Date:  2009-03-10       Impact factor: 3.252

7.  Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors.

Authors:  Christopher A Reilly; Jack L Taylor; Diane L Lanza; Brian A Carr; Dennis J Crouch; Garold S Yost
Journal:  Toxicol Sci       Date:  2003-05       Impact factor: 4.849

8.  Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.

Authors:  Marnie Duncan; Paul Millns; Darren Smart; James E Wright; David A Kendall; Vera Ralevic
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

9.  Inflammatory pain: the cellular basis of heat hyperalgesia.

Authors:  Jiehong Huang; Xuming Zhang; Peter A McNaughton
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

10.  Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.

Authors:  H-J Behrendt; T Germann; C Gillen; H Hatt; R Jostock
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.